3 results about "Kidney ischemia" patented technology

This invention discloses butylphthalide nanoparticles, comprising: a layered double hydroxide and butylphthalide, wherein the butylphthalide is loaded onto the layered double hydroxide. This invention also discloses a method for preparing the above-mentioned butylphthalide nanoparticles, comprising the following steps: mixing the layered double hydroxide, butylphthalide, and water, adsorbing, separating the solid and liquid phases, and drying to obtain butylphthalide nanoparticles. This invention further discloses the application of the above-mentioned butylphthalide nanoparticles in the preparation of drugs for treating acute renal ischemia-reperfusion injury. This invention also discloses a drug for treating acute renal ischemia-reperfusion injury, comprising: the above-mentioned butylphthalide nanoparticles and pharmaceutically acceptable excipients. The butylphthalide nanoparticles of this invention have high drug loading capacity, good stability, and can target and activate the PI3K-AKT signaling pathway, effectively inhibit HK-2 cell apoptosis and oxidative stress, restore mitochondrial function, and improve renal ischemia-reperfusion injury.

This invention discloses the application of quinolinic acid in the preparation of drugs for the prevention and treatment of acute kidney injury (AKI). AKI refers to acute kidney injury induced by renal ischemia-reperfusion. The drug is an oral formulation used for prophylactic administration in high-risk individuals undergoing iatrogenic procedures at potential AKI risk, and for pretreatment of ischemic conditions in transplanted kidneys. Experiments have shown that administration of quinolinic acid significantly reduces serum urea nitrogen levels in AKI mice, alleviates renal tissue morphological damage in AKI mice, and reduces the expression level of the renal tubular injury factor NGAL protein in AKI mice, demonstrating significant clinical value in the prevention and treatment of AKI.

This invention discloses a fluorescent probe for the specific detection of fatty acid amide hydrolases, its preparation method, and its applications, relating to the field of biomedical detection technology. The probe, named TMBID, has the structure shown in formula (I): (I). The structure includes a FAAH-specific recognition unit and a large Stokes shift red fluorophore. This probe has been demonstrated for the first time to selectively and sensitively visualize FAAH activity in renal cell carcinoma cells (ACHN, A498) and a renal ischemia-reperfusion injury (RIRI) model. In vitro experiments showed that TMBID's response to FAAH is not interfered with by other hydrolases (such as FAP-α, aminopeptidase N, etc.), and the URB597 inhibitor significantly suppressed the fluorescence signal by 67%. In cell experiments, TMBID could distinguish renal cell carcinoma cells (high fluorescence intensity) from normal kidney / hepatocytes (fluorescence intensity as low as 20%). Animal models confirmed its specific enrichment in renal cell carcinoma and RIRI tissues. This probe provides a revolutionary tool for early diagnosis of renal cell carcinoma, dynamic monitoring of renal injury, and FAAH-targeted therapy.